Is CADL a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Candel Therapeutics (CADL) rests on The prostate cancer filing in mid-2027: The PrTK03 Phase 3 trial tested aglatimagene plus valacyclovir added to standard radiation in intermediate-risk localized prostate cancer, against placebo plus radiation. The bear case rests on the main risk is regulatory. Analysts covering it publish targets from $11.00 to $29.00 against a $5.04 share price on November 20, 2026, so even the professionals disagree by 102% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
CADL key stats
At $5.04 on November 20, 2026, Candel Therapeutics (CADL) has a market cap of $395M.
- Market cap
- $395M
- Price to book
- 3.0
Market cap, P/E and yield are measured at the $5.04 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Candel Therapeutics (CADL)?
The last two weeks for Candel Therapeutics, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- CADL closed at $5.04 on November 20, 2026, down 18.7% over the past five trading days (from $6.20).
- On November 16, 2026, Citigroup lowered its target to $20.00 from $26.00 (Buy).
- On November 13, 2026, HC Wainwright & Co. lowered its target to $18.00 from $23.00 (Buy).
- On November 13, 2026, Canaccord Genuity lowered its target to $13.00 from $25.00 (Buy).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Candel Therapeutics is a Needham, Massachusetts biotech that builds viral immunotherapies: modified viruses injected straight into a tumor to make the immune system see it. Its lead drug, aglatimagene besadenovec (CAN-2409), is an adenovirus carrying a gene that, paired with the oral antiviral valacyclovir, kills tumor cells and releases tumor antigens. A second platform uses a modified herpes virus, linoserpaturev (CAN-3110), now in a Phase 1b trial in recurrent high-grade glioma. Candel sells nothing yet, so every dollar of spending comes from equity and debt. The third quarter of 2026, reported November 12, showed a net loss of ~$21.9M, up from ~$11.3M a year earlier. Research spending rose to ~$15.6M from ~$8.5M on trial and manufacturing costs, and administrative costs rose to ~$7.4M from ~$4.7M as the company prepared for a commercial launch. Cash was ~$203.1M on September 30, helped by a ~$100M share sale at $5.45 in February 2026 and the first ~$50M of a $130M Trinity Capital loan. Management says that cash lasts into the second quarter of 2028. The same release moved the Biologics License Application (BLA) for prostate cancer from the fourth quarter of 2026 to mid-2027, citing timelines for certain assay refinements and ongoing talks with the FDA. That delay is why the stock is trending. Shares closed at ~$8.39 on November 12, traded near ~$5.25 before the open on November 13, and closed at ~$5.11 on November 20, 2026, a market value of roughly ~$401M on ~78M shares. With ~$203M of cash and ~$50M of debt, the market is assigning about $250M of value to the whole pipeline, including a drug with positive Phase 3 data under a Special Protocol Assessment. Stifel kept a Buy rating but cut its target to $19 from $22, saying commercial launch now looks like mid-2028, and BofA Securities cut its target to $15 from $18. The investment case rests on the prostate filing going in on the new date, an FDA approval, and the Phase 3 AURORA lung cancer trial, which started enrolling this quarter.
The bull case: what would have to be true for $29.00
The most optimistic published target on CADL is $29.00, +475.4% from the $5.04 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. The prostate cancer filing in mid-2027
The PrTK03 Phase 3 trial tested aglatimagene plus valacyclovir added to standard radiation in intermediate-risk localized prostate cancer, against placebo plus radiation. At a median follow-up of 58 months, patients on the drug had a 41% lower risk of recurrence or prostate cancer-specific death (p=0.0034). At two years, 80% of treated patients had negative biopsies versus 63% of controls. The trial ran under a Special Protocol Assessment, an FDA agreement on design and endpoints, and the drug has Fast Track and RMAT designations, which allow rolling review and closer FDA contact. A filing in mid-2027 and a standard review would put a decision around mid-2028, the date Stifel now uses for launch.
2. Manufacturing readiness
Candel says it has finished a process validation campaign for drug substance and drug product at its contract manufacturer, has made clinical material with the new process, and is testing validation batches meant for commercial supply. For a viral gene therapy, chemistry, manufacturing and controls (CMC) work is often what decides whether a BLA is accepted and approved on time. The delay announced in November was tied to assay refinement, which sits in this same body of work. Investors will look for the company to confirm, probably in early 2027, that the assays are locked and that the FDA agrees on the package. Any further slip would likely push the launch into late 2028 and shorten the gap before cash runs out.
3. AURORA, the Phase 3 lung cancer trial
Candel's second large opportunity is metastatic non-squamous non-small cell lung cancer (NSCLC) in patients whose disease kept growing on checkpoint inhibitors such as Keytruda. In a Phase 2a trial published in the Journal for ImmunoTherapy of Cancer, patients given aglatimagene with continued checkpoint therapy had a median overall survival of ~24.5 months in the evaluable group. Standard chemotherapy (docetaxel) in this setting has historically produced survival closer to a year. AURORA randomizes patients 1:1 to aglatimagene plus continued pembrolizumab or to docetaxel, with overall survival as the primary endpoint, across ~150 planned sites. The first site opened in the third quarter of 2026, so results are several years away, but the trial gives the stock a second shot beyond prostate cancer.
4. Funding through approval
Candel had ~$203M of cash on September 30, 2026 and reported operating expenses of ~$23M in the third quarter, up from ~$13M a year earlier as AURORA and launch preparation ramp. Management guides that cash reaches into the second quarter of 2028, which is close to the new expected approval window. The Trinity Capital facility has up to ~$80M more available: two tranches totaling $50M tied to milestones and a $30M tranche at the lender's discretion. If milestones shift with the BLA, access to that money could shift too. The cheaper path would be raising equity after an approval, while a raise near today's lower price would dilute holders more than the February sale at $5.45 did.
The bear case: what would have to be true for $11.00
The most pessimistic published target is $11.00, +118.3% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Candel Therapeutics is worth if the risks below bite instead of the drivers above.
The main risk is regulatory. The BLA has already moved once, from late 2026 to mid-2027, and the company says the timing still depends on FDA discussions, so another delay is possible. The FDA could also question the trial's endpoint, the size of the benefit, or the comparison with current care, which in intermediate-risk patients often adds short-course hormone therapy to radiation. Manufacturing is a second risk: viral gene therapies have drawn FDA complete response letters over CMC issues, and assay work is the cause of the current delay. Financing is a third. Cash lasts into Q2 2028, about when an approval could come, so a further slip probably means raising money at a depressed share price; the Trinity loan's later tranches depend on milestones. Lung cancer is a fourth: AURORA is a large, costly trial and a Phase 2a survival figure from a single-arm study often shrinks in randomized testing. Short interest was ~17% of shares outstanding before the drop, which can make the stock move sharply in both directions. With no revenue, the share price has no earnings floor.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CADL already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on CADL
9 analysts cover CADL, with an average target of $17.67 (+250.6% against $5.04) and a split of 10 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CADL forecast and price target page.
How is CADL valued?
Market cap, P/E and dividend yield at today's price are in the CADL key stats above. The business figures below come from Candel Therapeutics's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$0; no approved products
- Net loss: ~$21.9M in Q3 2026 (EPS about -$0.28 vs ~-$0.31 expected); ~$69.6M for the first nine months
- Operating expenses: ~$23.0M in Q3 2026, up from ~$13.2M a year earlier
- Cash (Sept 30, 2026): ~$203M; runway guided into Q2 2028
- Debt: ~$50M drawn on a $130M Trinity Capital term loan
- Analyst view: Average target ~$17.67 across 9 analysts (November 2026), down from ~$22 before the delay
As of November 2026: With no sales, Candel is valued on its pipeline. At about $5.11 per share on November 20, 2026, the market cap is about $401M and enterprise value about $250M after netting ~$203M of cash against ~$50M of debt. That is the price the market puts on a drug with positive Phase 3 prostate data, a Phase 3 lung trial just started and an early glioma program. Analysts' average target was ~$22 before the delay and is about ~$17.67 across nine analysts after cuts from Stifel (to $19) and BofA (to $15), which shows how much of the gap depends on approval timing and dilution. A clean filing in mid-2027 or a further slip would likely move this valuation more than any quarterly loss figure.
How do you decide if CADL is a buy?
Whether CADL is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CADL indirectly through an index or sector ETF before adding more.
What would change your mind on CADL
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: The prostate cancer filing in mid-2027 stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: the main risk is regulatory fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the CADL stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CADL against your real portfolio and see your actual exposure before deciding.
Your questions about Candel Therapeutics
Ask Walnut's AI anything about CADL and see how it fits what you own.
FAQ
Is CADL a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on The prostate cancer filing in mid-2027, with revenue (ttm) at ~$0; no approved products. The bear case rests on the main risk is regulatory. Analysts covering it are spread from $11.00 to $29.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell CADL?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The main risk is regulatory. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $11.00, +118.3% from the $5.04 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for CADL?
+
The prostate cancer filing in mid-2027. The PrTK03 Phase 3 trial tested aglatimagene plus valacyclovir added to standard radiation in intermediate-risk localized prostate cancer, against placebo plus radiation. The most optimistic analyst target on CADL is $29.00, +475.4% from the $5.04 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for CADL?
+
The main risk is regulatory. The BLA has already moved once, from late 2026 to mid-2027, and the company says the timing still depends on FDA discussions, so another delay is possible. The FDA could also question the trial's endpoint, the size of the benefit, or the comparison with current care, which in intermediate-risk patients often adds short-course hormone therapy to radiation. Manufacturing is a second risk: viral gene therapies have drawn FDA complete response letters over CMC issues, and assay work is the cause of the current delay. Financing is a third. Cash lasts into Q2 2028, about when an approval could come, so a further slip probably means raising money at a depressed share price; the Trinity loan's later tranches depend on milestones. Lung cancer is a fourth: AURORA is a large, costly trial and a Phase 2a survival figure from a single-arm study often shrinks in randomized testing. Short interest was ~17% of shares outstanding before the drop, which can make the stock move sharply in both directions. With no revenue, the share price has no earnings floor. The most pessimistic published target is $11.00, +118.3% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Candel Therapeutics do?
+
Candel Therapeutics is a Needham, Massachusetts biotech that builds viral immunotherapies: modified viruses injected straight into a tumor to make the immune system see it.
What would have to change for CADL to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The prostate cancer filing in mid-2027) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the main risk is regulatory) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
Why did CADL stock fall on November 13, 2026?
+
On November 12, alongside its third-quarter results, Candel said it now expects to submit the BLA for aglatimagene besadenovec in localized prostate cancer in mid-2027. The prior target was the fourth quarter of 2026, so the filing slipped about six months. The company cited timelines for certain assay refinements and said final timing depends on ongoing FDA discussions. Shares closed at ~$8.39 on November 12, already down ~9% on the day, and then traded near ~$5.25 before the open on November 13, a drop of roughly 37%. The stock had more than doubled earlier in 2026 on expectations of a year-end filing, which made the reaction to the delay larger. Stifel cut its price target to $19 from $22 and kept a Buy rating, saying launch expectations move to mid-2028.
What is aglatimagene besadenovec (CAN-2409)?
+
Aglatimagene besadenovec is an adenovirus engineered to carry the herpes simplex virus thymidine kinase gene. It is injected directly into the tumor, and the patient then takes valacyclovir, a common oral antiviral. Inside infected tumor cells, the enzyme turns valacyclovir into a toxic compound that kills those cells. As the cells die, they release tumor antigens, and the virus itself draws immune cells in, so the treatment works partly as a local vaccine against the patient's own cancer. Candel reported that in its PrTK05 Phase 2 study, treated patients showed higher levels of CD8+ T cells and memory T cells in the blood. The drug holds Fast Track and RMAT designations in prostate cancer, Fast Track in NSCLC, and Fast Track plus Orphan Drug designations in pancreatic cancer.
How strong were the Phase 3 prostate cancer results?
+
In the PrTK03 Phase 3 trial in intermediate-risk localized prostate cancer, adding aglatimagene and valacyclovir to radiation cut the risk of recurrence or prostate cancer-specific death by 41% versus placebo plus radiation (p=0.0034), at a median follow-up of 58 months. In the exploratory longer follow-up, Candel reported improvements of 52% in time to biochemical failure, 49% in time to salvage therapy and 90% in time to metastasis. At two years, 80% of treated patients (n=167) had negative biopsies, against 63% of controls (n=62). The trial ran under a Special Protocol Assessment, which records FDA agreement on the design. These are company-reported figures, and the FDA will reach its own view of the data and the benefit for patients during review.
Walnut is informational, not investment advice, and gives no verdict on CADL. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.